您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > CYM-5541(ML249)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
CYM-5541(ML249)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CYM-5541(ML249)图片
CAS NO:945128-26-7
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW) 316.45
Formula C19H28N2O2
CAS No. 945128-26-7
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: ≥ 40 mg/mL
Water: N/A
Ethanol: N/A
Chemical NameN,N-dicyclohexyl-5-cyclopropyl-3-isoxazolecarboxamide
SynonymsML249; ML 249; ML-249; CYM-5541; CYM 5541; CYM5541
SMILES CodeO=C(C1=NOC(C2CC2)=C1)N(C3CCCCC3)C4CCCCC4
实验参考方法
In Vitro

In vitro activity: CYM-5541 (also known as ML249) is a potent, selective, and allosteric agonist of the S1P3 (Sphingosine 1-phosphate) receptor with EC50 in the range of 72 to 132 nM. S1P is a lysophospholipid signaling molecule that regulates important biological functions, including lymphocyte trafficking and vascular development, by activating G protein-coupled receptors for S1P, namely, S1P(1) through S1P(5). CYM-5541 was used to to identify an allosteric site where Phe263 is a key gate-keeper residue for its affinity and efficacy. This ligand lacks a polar moiety, and the novel allosteric hydrophobic pocket permits S1P(3) selectivity of CYM-5541 within the highly similar S1P receptor family.


Kinase Assay:

ELISA for p44/42 MAPK Phosphorylation: Ligand-mediated ERK phosphorylation was measured using PathScan Phospho-p44/42 MAPK (Thr202/Tyr204) Sandwich ELISA kit (Cell Signaling Technology). Cells expressing WT or mutant S1P3were serum-starved for 4 hr. In the antagonist experiments, cells were either pre-incubated with SPM-242 at 1 uM for 15 min before agonist treatment or 1 uM SPM-242 was pre-mixed with agonists. Cells were then stimulated for 5 min (determined to give maximal ERK phosphorylation for all agonists) with increasing concentrations of S1P or CYM-5541 and phosphorylation of p44/42 MAPK was assayed according to manufacturer’s protocol. The dose response curves for agonist-mediated p44/42 MAPK phosphorylation were analyzed and EC50 was determined using Prism (Graphpad Software).

[33P]S1P Radioligand Binding Assay: Jump-In TI CHO-K cells (5 × 105) stably expressing WT or mutant S1P3 were serum-starved for 4 hrs. They were then incubated at 4 °C for 30 min in the binding buffer containing 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 15 mM NaF, 0.5 mM EDTA, 1 mM Na3VO4, 0.5% fatty acid-free bovine serum albumin, and protease inhibitor mixture (Roche) with 0.1 nM [33P]S1P and increasing concentrations of S1P, SPM-242, or CYM-5541. Cells were washed three times with cold binding buffer. Cell-bound radioactivity was measured by lysing the cells with 0.5% SDS followed by liquid scintillation counting. The raw data was normalized so that the level of [33P]S1P bound to each cell line (WT or mutant) in the absence of competing ligand was referenced as 100% for its own cell line.


Cell Assay: Plasmid encoding N-terminal, triple HA-tagged S1P3 fusion protein in pcDNA3.1 was purchased from cDNA.org. S1P3 receptor mutants were generated by overlapping PCR mutagenesis, and sequences were verified prior to use. Jump-In(TM) TI(TM) CHO-K parental cells, Gateway cloning vectors (pDONR 221, pJTI R4 DEST, and pJTI R4 Int), and enzymes (BP clonase II and LR clonase) were purchased from Invitrogen Corp. Triple HA-tagged WT and mutant S1P3 were first cloned into entry clones using the BP recombination reaction. They were retargeted into an appropriate pJTI R4 DEST vector to yield a pJTI R4 EXP retargeting expression vector. Jump-In TI CHO-K cells were transfected with both pJTI R4 EXP S1P1 and pJTI R4 Int vector for retargeting. After expanding retargeted cells, retargeted Jump-In TI cells were selected using blasticidin at 10 μg/mL for 4 weeks.

In Vivo
Animal model
Formulation & Dosage
References ACS Chem Biol. 2012 Dec 21;7(12):1975-83.